sterna biologicals to attend international partnering and investor conferences in November

Marburg, Germany, November 07, 2019 
Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announced that the Company will participate and present at the following partnering and investor conferences in November:

sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement

Marburg, Germany, May 26, 2020

  • Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis 
  • Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes 
  • Topical treatment with SB010 and SB012 is expected to become a novel, safe and efficacious therapeutic option for chronic inflammatory diseases with high unmet medical need. 

sterna biologicals strengthens management team to progress towards phase IIB development

Marburg, Germany, 08 July 2019

  • Industry veteran Dr. Marion Wencker strengthens sterna’s management team as consulting CMO
  • Financial expert Dr. Thomas Klaue recently joined sterna as consulting CFO

sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel biological treatments for chronic inflammatory diseases, announced today that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.

sterna biologicals invited to present at the GOODWIN - SOLEBURY TROUT - NASDAQ european biotech investor day 2019

Marburg, Germany, 25 July 2019

  • sterna biologicals selected as one of a group of top-tier European biotech companies to present at the European Biotech Investor Day on August 1, 2019 in New York City
  • CEO Christian Pangratz to discuss the Company’s robust development progress and next phase of growth fueled by sterna’s first-in-class DNAzyme hgd40 in Phase 2 development for asthma and ulcerative colitis

Successfull device feasibility studies with sterna biologicals asthma drug candidates SB010 enables select of optimal nebulizers for late-stage development and commercialization

Marburg, Germany, September 05, 2018 

  • Feasibility studies show excellent data with SB010 across a selection of high efficiency hand-held nebulizers
  • Company well positioned to advance SB010 into late-stage clinical development

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has successfully completed in vitro device feasibility studies with its asthma drug candidate, SB010. These studies support the selection of the most efficient and user-friendly device options for late-stage development and commercialization of SB010.